Research programme: wound healing therapeutics - Pacific Northwest Biotechnology
Latest Information Update: 08 Aug 2011
At a glance
- Originator Pacific Northwest Biotechnology
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Preclinical Wounds
Most Recent Events
- 07 Aug 2011 Preclinical development is ongoing in USA
- 03 Dec 2007 Preclinical trials in Wounds in USA (Topical)